A Comprehensive Review of Natural Products as Therapeutic or Chemopreventive Agents against Head and Neck Squamous Cell Carcinoma Cells Using Preclinical Models

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that arises from the epithelium lining of the oral cavity, hypopharynx, oropharynx, and larynx. Despite the advancement of current treatments, including surgery, chemotherapy, and radiotherapy, the overall survival rate of patients afflicted with HNSCC remains poor. The reasons for these poor outcomes are due to late diagnoses and patient-acquired resistance to treatment. Natural products have been extensively explored as a safer and more acceptable alternative therapy to the current treatments, with numerous studies displaying their potential against HNSCC. This review highlights preclinical studies in the past 5 years involving natural products against HNSCC and explores the signaling pathways altered by these products. This review also addresses challenges and future directions of natural products as chemotherapeutic and chemoprevention agents against HNSCC.


Introduction
Head and neck cancer (HNC) represents cancers occurring in the head and neck region, which includes the lip and oral cavity, nasal cavity, larynx, and pharynx [1].More than 90% of HNCs are head and neck squamous cell carcinomas (HNSCCs), which account for approximately 300,000 deaths and 500,000 new cases worldwide annually [2].In the United States, HNSCC has been diagnosed as one of the top 10 leading cancers in men in 2022 [2][3][4].The low survival rate of HNSCC has been proposed to be associated with cancer recurrence, distant metastases, the progression of second primary cancers, and resistance to chemo/radiotherapy [5,6], making it a public health issue that compromises patients' quality of life.
Tobacco smoking, excessive alcohol drinking, betel quid chewing, and high-risk human papillomavirus (HPV) have been documented as risk factors for HNSCC [7][8][9][10].Clinical intervention of HNSCC often takes place at advanced stages of the disease due to late diagnoses, especially among individuals with a lower socioeconomic background [11,12].The most common clinical interventions for HNSCC are surgery, radiotherapy, chemotherapy, or combined therapy, which causes numerous side effects during the treatment of this disease [11].However, even with a successful clinical intervention, approximately 30% of these patients treated at advanced stages of the disease develop recurrent locoregional or second primary cancers, with the onset of chemo-or radio-resistance [13][14][15].Notably, these clinical interventions are only effective on a limited subgroup of HNSCC patients and often result in additional morbidities.
Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody, was the first molecular-targeted drug approved by the U.S. Food and Drug Administration (FDA) as a chemotherapeutic agent for HNSCC in 2006 [5,16].A retrospective study in Japan reported a total effective rate of 57.1%, a median progression-free survival (PFS) of 5.5 months, and an overall survival (OS) of 8.0 months with cetuximab in locally advanced HNSCC, while a total effective rate of 60.0%, a PFS of 3.8 months, and an OS of 5.8 months were reported in distantly metastatic HNSCC [17].However, the chemoresistance ability of certain mutated cancer cell types, such as EGFRvIII, has shown resistance toward cetuximab [18].In recent years, both pembrolizumab and nivolumab, which act as anti-programmed cell death receptor 1 (PD-1) immunotherapy drugs, were approved by the FDA for recurrent or metastatic HNSCC treatment [19,20].However, most patient previously exposed to anti-PD-1 monoclonal antibody develop acquired resistance to immunotherapeutic drugs, making it difficult to treat recurrent or metastatic cancers [21].There is certainly an urgent need for alternative therapeutic agents to overcome the acquired resistance of HNSCC to the standard of care.Because of the challenges faced using immunotherapies, there is a great need for therapeutic agents that can work effectively as chemoprevention or to enhance the effectiveness of chemotherapeutic agents when used in combination to kill cancer cells.
Natural products are compounds naturally found in natural resources such as plants, which possess biological activities [22].In recent years, natural products have been widely reported for their chemotherapeutic and chemoprevention properties against HNSCC due to their low cytotoxicity, efficacy against cancers, availability, and low cost [12,22].According to U.S. National Cancer Institute, chemoprevention is defined as the use of certain drugs or other substances to help lower a person's risk of developing cancer or keep it from coming back [23].The beneficial properties of natural products are consistent and could overcome the challenges with current treatment such as acquired chemoresistance, cytotoxicity against normal cells, and expensive therapy.Numerous studies have been carried out with various natural products on preclinical models of HNSCC, including various HNSCC cell lines and xenograft or carcinogen-induced tumor animal models (Figure 1).For example, psorachromene, a flavonoid found in Psoralea corylifolia, which has been used in traditional Chinese medicine (TCM) and Ayurveda, had shown therapeutic effects against HNSCC via regulation of the EGFR signaling pathways and other carcinogenesis-related signaling pathway, making it a strong candidate to act as a chemotherapeutic agent [24].Other natural products, such as calcitriol, have been reported to possess chemoprevention properties against carcinogen-induced HNSCC in animal models [25].Therefore, natural products have shown potential as candidates for further exploration as adjuvant, neoadjuvant chemotherapy, and chemoprevention agents in HNSCC.However, we acknowledge that, in many cases, these compounds are studied only at the beginning state in animal models.More studies on safety and efficacy are needed to improve the therapeutic potential in patients, which include clinical trials.
The activation of complex signaling pathways, such as phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) and mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK), is important for tumor development, cell survival, and angiogenesis, while epithelial to mesenchymal transition (EMT) signaling leads to tumor invasion and migration [26,27].Thus, the inhibition of these signaling pathways could lead to cell death, inhibiting tumor development and metastasis [27].Notwithstanding the extensive knowledge at the molecular level of tumor-associated signaling pathways, the chemotherapeutic agents targeting the oncogenic pathways are limited [28].To date, Crooker et al. and Rahman et al. have described the use of natural products as chemoprevention agents against HNSCC [29,30].Several natural products, such as vitamin A, green tea extract, and curcumin, which have shown promising results in preclinical studies, were reported to show toxicity with limited bioavailability in clinical studies [31][32][33][34].Vitamin A has been shown by Shin et al. [31] and Papadimitrakopoulou et al. [33] to induce toxicity via oral mucosa and lip inflam-mation, conjunctivitis, skin reactions, fatigue, and joint and muscle pain.On the other hand, poor oral absorption of green tea extract and curcumin has been observed, which limits the bioavailability of both natural products [33,34].Other emerging chemotherapeutic phytochemicals or herbal derivatives against HNC have recently been described by Aggarwal et al. [12].However, several new phytochemicals against HNSCC, such as actein, calcitriol, and psorachromene, were not fully addressed.Therefore, in this review, the comprehensive mechanisms of various natural products showing significant preclinical results in HNSCC models for the past 5 years are discussed.
inflammation, conjunctivitis, skin reactions, fatigue, and joint and muscle pain.On the other hand, poor oral absorption of green tea extract and curcumin has been observed, which limits the bioavailability of both natural products [33,34].Other emerging chemotherapeutic phytochemicals or herbal derivatives against HNC have recently been described by Aggarwal et al. [12].However, several new phytochemicals against HNSCC, such as actein, calcitriol, and psorachromene, were not fully addressed.Therefore, in this review, the comprehensive mechanisms of various natural products showing significant preclinical results in HNSCC models for the past 5 years are discussed.

PI3K/Akt/mTOR Pathway
It was previously reported that the activation of the PI3K/Akt/mTOR pathway has been observed in approximately 90% of HNSCC cases, making it a prominent target for treatments of HNSCC [35,36].The activation of PI3K/Akt/mTOR signaling also plays an important role in HNSCC chemotherapy and radiotherapy resistances, as the inhibition of the signaling pathway has shown positive effects on tumor proliferation and radiotherapy sensitization in preclinical studies [37,38].The PI3K/Akt/mTOR pathway is activated when a ligand-like growth factor binds with the receptor tyrosine kinase (RTK), leading to the activation of PI3K, which, in turn, partially activates Akt [39].Then, mTORC2 is required to completely activate Akt via phosphorylation, leading to the activation of multiple proteins involved in cell proliferation and motility [40].Inhibition of Akt formation will therefore limit the expression of oncoprotein.Various natural products, namely actein, salicylate, tanshinone IIA, xanthohumol, fucoidan, honokiol, ilimaquinone, nimbolide, and cinnamaldehyde, have led to the downregulation of Akt expression and phosphorylation of Akt (p-Akt) using HNSCC preclinical models [41][42][43][44][45][46][47][48][49].The downregulation of mTOR expression in HNSCC preclinical models has been shown by salicylate,  It was previously reported that the activation of the PI3K/Akt/mTOR pathway has been observed in approximately 90% of HNSCC cases, making it a prominent target for treatments of HNSCC [35,36].The activation of PI3K/Akt/mTOR signaling also plays an important role in HNSCC chemotherapy and radiotherapy resistances, as the inhibition of the signaling pathway has shown positive effects on tumor proliferation and radiotherapy sensitization in preclinical studies [37,38].The PI3K/Akt/mTOR pathway is activated when a ligand-like growth factor binds with the receptor tyrosine kinase (RTK), leading to the activation of PI3K, which, in turn, partially activates Akt [39].Then, mTORC2 is required to completely activate Akt via phosphorylation, leading to the activation of multiple proteins involved in cell proliferation and motility [40].Inhibition of Akt formation will therefore limit the expression of oncoprotein.Various natural products, namely actein, salicylate, tanshinone IIA, xanthohumol, fucoidan, honokiol, ilimaquinone, nimbolide, and cinnamaldehyde, have led to the downregulation of Akt expression and phosphorylation of Akt (p-Akt) using HNSCC preclinical models [41][42][43][44][45][46][47][48][49].The downregulation of mTOR expression in HNSCC preclinical models has been shown by salicylate, honokiol, cinnamaldehyde, and Seco-A-ring oleanane, with PI3K also limiting the phosphorylation of Akt [42,45,48,50].The expression of glycogen synthase kinase-3β (GSK-3β) plays an important role in regulating growth, cell cycle progression, apoptosis, and cancer cell invasion in HNSCC [51,52].The inactivation of GSK-3β via phosphorylation has previously shown significant inhibition in cancer cell growth and migration in HNSCC [51].Preclinical studies with nimbolide have also shown the upregulation of phosphorylated GSK-3β, inactivating GSK-3β and thus inhibiting cell proliferation [47].The expression of c-Myc has been associated with the upregulation of Akt-related pathways, leading to cancer cell proliferation and tumorigenesis [53].The downregulation of c-Myc using HNSCC preclinical models has been observed with tanshinone IIA, leading to the inhibition of tumorigenesis [43].
Actein, a biologically active compound found in the rhizome of Cinicifuga foetida, has been discovered to inhibit forkhead box O1 (FoxO1) by upregulating the phosphorylation of FoxO1 (p-FoxO1), leading to the inhibition of cell proliferation via the Akt/FoxO1 signaling pathway [41].Knockdown of FoxO1 would reverse the antiproliferation properties of actein, indicating that the Akt/FoxO1 pathway plays an important role in actein-induced effects toward HNSCC [41].FoxO1 is one of many transcription factors among the FoxO family which regulates various biological activities in HNSCC, such as cancer cell invasion and proliferation [73].
Activated p53 via phosphorylation acts as a tumor suppressive molecule, which has been associated with induced apoptosis in HNSCC [74,75].About half of HNSCC cases have shown a loss-of-function p53 gene mutation [76], making p53 an interesting target in improving the efficiency of HNSCC therapy through the reactivation of p53.In HPV-positive HNSCC, p53 was downregulated by the E6 oncoprotein, leading to tumorigenesis [76].Notably, neferine and ilimaquinone have been shown to upregulate or activate p53 in preclinical HNSCC studies, leading to apoptosis [46,64].

LC3-Dependent Autophagy
Autophagy is a major process involving protein degradation followed by the turnover of cellular components, which helps maintain the intercellular homeostasis [77].Light chain 3 (LC3) has been strongly associated with the regulation of autophagosome, a doublemembrane vesicle formed during autophagy [77,78].During the formation of an autophagosome, cytosolic LC3 (LC3-I) is converted into the activated form of intra-autophagosomal LC3 (LC3-II) via a uibiquitylation-like reaction catalyzed by Atg7 and Atg3, by conjugating with phosphatidylethanolamine [77][78][79].Therefore, the increased conversion of LC3-I to LC3-II indicates higher levels of autophagosome and thus the activation of autophagy, leading to tumor suppression [80].The accumulation of p62 was also found to be associated with the induction of autophagy in HNSCC [81].Honokiol, ilimaquinone, and nimbolide have been reported to increase LC3-II/LC3-I ratio in HNSCC preclinical models [42,45,47].
Paradoxically, autophagy may potentially lead to tumor survival when certain conditions are met [82][83][84][85].Hypoxia, a condition where the oxygen level is below the physiological level, is a common feature in tumor progression when the oxygen supply does not meet the demand due to the exponential growth of tumor [83,86].Hypoxia-induced autophagy in tumors has been observed to induce tumor survival in vitro [83].Meanwhile, the knockdown of essential autophagy proteins with a xenograft model was found to promote tumor suppression [84].The turnover of cellular components by autophagy may essentially help with hypoxia and nutrient stress faced by exponentially growing tumors, thus enhancing tumor survival [83,84].

Cell Cycle Arrest by Cyclin and the CDK Signaling Pathway
The cell cycle acts as a fundamental process for cancer progression in HNSCC, including cell proliferation and differentiation [95].It is well established that cyclins and cyclin-dependent kinases (Cdks) play an important role in the regulation and transition of cell cycles [96][97][98].G0/G1 transitioning is strongly dependent on cyclin-D/Cdk4/6 complexes; S phase entry is dependent on the cyclin E/Cdk2 complex; S/G2 transitioning is dependent on the cyclin A/Cdk2 complex, followed by mitotic phase entry, which is dependent on the cyclin A/Cdk1 complex, and finally, M/G0 transitioning, which is dependent on the cyclin B/Cdk1 complex [99][100][101][102][103].The inhibition of the cell cycle via the formation of cyclin-Cdk complexes would lead to cell cycle arrest and, eventually, cell death in HNSCC [104].Anti-mitogenic signals such as p16, p21, and p53 could inhibit the cell cycle transition effectively by inhibiting the formation of cyclin-Cdk complexes, thus acting as an important target for cell cycle arrest induction [99,105,106].Xanthohumol, neferine, fucoidan, hydroxygenkwanin, ilimaquinone, honokiol, trichodermin, cinnamaldehyde, resveratrol, and curcumin have been discovered to induce cell cycle arrest via cyclin-dependent signaling with HNSCC preclinical models [44][45][46]48,49,56,64,107,108].

Chemoprevention Properties of Natural Products against HNSCC Oral Carcinogenesis Mechanism
Oral carcinogenesis often involves the formation of abnormalities in the oral tissue, known as oral potentially malignant disorder (OPMD), before proceeding to oral squamous cell carcinoma (OSCC), a major type of HNSCC [111,112].Previous studies have found the malignant transformation (MT) rate of OPMD to be 7.9%, while high-risk OPMD, such as erythroplakia, has shown an average MT rate of 33.1% [113].To date, no preventive strategies including the use of drugs and/or surgical procedures has been considered the standard of care for OPMDs, thus indicating the need to investigate the chemoprevention properties of various natural products against oral carcinogenesis [114].Several drugs, such as celecoxib, erlotinib, and metformin, have been investigated for their HNSCC prevention properties via clinical trials on oral premalignant lesions [115][116][117].However, the use of erlotinib and celecoxib has shown no significant result in reducing the oral cancer-free survival rate while possessing higher toxicity [115,116].The use of metformin has shown a low clinical response rate (17%) in terms of reduction in lesion size [117].
In vivo studies involving the use of genetically altered rodents or rodents treated with chemical carcinogens could lead to site-specific carcinogenesis, mimicking carcinogenesis in humans [118].Moreover, 4-nitroquinoline 1-oxide (4NQO) acts as a tobacco-mimicking carcinogen, which has been widely used in carcinogen-induced HNSCC animal models, mainly due to the similarity in terms of genetic alteration and expression between 4NQOinduced mouse models and human oral carcinogenesis [119,120].Other carcinogens, including 7,12-dimethylbenz(a)anthracene (DMBA) and dibenzo[a,l]pyrene (DBP), have also been widely used as HNSCC-inducing agents in animal models [64,121].
Several review studies have introduced various natural products as chemoprevention agents against HNSCC, where vitamin A, green tea extracts, and curcumin have shown promising results in preclinical and clinical trials [29,30].However, vitamin A has shown toxicity [31,32], while green tea extracts and curcumin [33,34] have both shown limitations in bioavailability.In a randomized chemoprevention trial reported by Papadimitrakopoulou et al. [32], low-dose 13-cis retinoic acid (a derivative of vitamin A) could induce grade 1 (45%), 2 (37%), 3 (15%), and 4 (1%) toxicity, including cheilitis, conjunctivitis, and skin reactions.Similarly, a phase II chemoprevention trial by Shin et al. [31] with combinations of interferon-alpha, 13-cis retinoic acid, and alpha-tocopherol induced mild to moderate non-hematologic toxicity.One patient was reported with a severe throat infection due to beta-hemolytic streptococci which required an emergency tracheostomy.The patient was still able to complete the planned treatment after fully recovering from the infection [31].Green tea extract was reported to induce adverse effects such as insomnia, nausea, nervousness, and headache, which is most likely due to the presence of caffeine in green tea extract [33].The poor oral absorption of epigallocatechin-3-gallate, the most abundant polyphenol in green tea extract, was reported by Tsao et al. [33], leading to variability in plasma epigallocatechin-3-gallate concentrations.Similarly, a phase I chemoprevention trial by Cheng et al. [34] with curcumin also indicated the poor gastrointestinal absorption of curcumin, as the peak serum curcumin concentration was recorded at 1.77 µM with 8000 mg daily dosage.The poor bioavailability of both green tea extract and curcumin have introduced difficulties in dosage estimation as absorption varies among patients, which may lead to ineffective treatment.Therefore, in this review, we seek to provide a greater variety of promising natural products with chemoprevention properties using 4NQO, DMBA, or DBP-induced carcinogenesis animal models [25,64,121].Table 3 summarizes preclinical studies with natural products involved in the chemoprevention of HNSCC investigated in the past 5 years.Preclinical in vivo studies involving neferine and nimbolide have indicated an inhibition in carcinogenesis and a reduction in the tumor growth of DMBA-induced HN-SCC, making both possible chemoprevention agents [41].Similarly, calcitriol successfully inhibited 4NQO-induced HNSCC carcinogenesis [25].Interestingly, a study by Vincent-Chong et al. [25] with calcitriol on a 4NQO-induced animal model showed the influence of treatment stage intervention and duration of exposure to treatment in carcinogenesis.Understanding the pathways involved during carcinogenesis will allow effective treatment intervention in HNSCC patients.
Calcitriol, nimbolide, and neferine are being investigated in preclinical studies for chemoprevention, and these products have shown promising results by reducing or inhibiting carcinogenesis-related molecular mechanisms [25, 47,64].

Limitation and Future Direction
As multiple signaling and crosstalk between pathways occur during carcinogenesis, with most recurrent or metastatic HNSCC failing the primary standard of care, an effective treatment for cancer may require a combined therapeutic approach such as the use of multiple signaling inhibitors combined with DNA-damaging drugs for the most efficient outcome [26].Therefore, the synergic or antagonistic effects of natural products with standards of care such as chemotherapy (cisplatin, cetuximab, pembrolizumab and nivolumab) and radiotherapy should be analyzed using preclinical models.However, fewer than 10% of the reviewed studies reported the combination effects of natural products with the standard of care.For instance, xanthohumol, psorachromene, honokiol, calcitriol, and salicylate were shown to provide synergistic effects with standard-of-care treatment such as chemotherapy and radiotherapy using HNSCC preclinical models [24,25,42,44,45].
The major reason for the low survival rate of HNSCC is due to late diagnoses and risk factors associated with HNSCC progression, which lead to the risk of recurrent or metastatic SCC [5,12].Chemoprevention therapy could potentially act as an important barrier to lower the risk of recurrent or metastatic SCC and the malignant transformation of OPMD; therefore, chemoprevention should be widely studied in the future.The prevention of HNSCC involving single-agent chemotherapy, such as retinoids and isotretinoin, possesses high toxicity and low efficacy, indicating the need for the development of new chemoprevention agents either as alternative or adjunctive agents for HNSCC prevention.In the current review, only 5 out of 37 studies explored the potential usage of natural products as chemoprevention therapy using 4NQO/DMBA/DBP-induced oral carcinogenesis [25,47,64,121].Furthermore, the stage and duration of natural products' intervention on oral carcinogenesis should also be extensively explored given the [25] strong association with the progression of carcinogenesis.All six natural products (Table 3) are strongly encouraged to proceed with clinical trials for high-risk OPMD patients, as previous trials with celecoxib, erlotinib, and metformin on mild to advanced OPMD showed no significant clinical improvements [115][116][117].
A preclinical study reported by Dai et al. [122] using various cancer lines (melanoma, breast, colon, and liver cancer cell lines (H1299, BT549, MDA-MB-231, MDA-MB-468, SW620, MHCC97H, and B16F10)) indicated the crucial role of immunomodulatory roles of natural products in anti-cancer treatments, including the involvement of CD3+ CD8+ T lymphocytes in a co-culture system together with cancer cell lines.Similarly, Cattanaeo et al. [123] and Neal et al. [124] have proposed the use of co-culture organoid-tumor reactive T lymphocyte system to investigate the role of anti-PD-1 drugs on T lymphocyte activity.Other studies have also used similar systems to screen natural product-derived drugs and epigenetic inhibitors for the non-cytotoxic T lymphocyte immunomodulating effects [122,125].Apart from the in vitro co-culture system proposed, Verma et al. [126] implemented an in vivo RPMOC1 synergic HNSCC animal model to investigate the effects of a non-oncological drug, calcitriol, on the immunomodulation of T lymphocytes, which was the only preclinical study involving synergic HNSCC in an in vivo model present at the time of preparing this review.The initiation of this review was prompted by a recent publication by Crooker et al. [29] which provided informaion on the use of natural products in HNSCC preclinical models in 2018.Over the past five years, there have been limited efforts to publish reviews related to natural products, with one notable publication by Aggarwal et al. [12] focusing solely on HPV-related HNSCC.To address the paucity of information, we explored the possibilities of using the latest research of natural products with in vitro and in vivo studies, listed in Tables 1-3, that has not been discussed in previous review papers, particularly targeting HNSCC, as some signaling pathways are common among different subtypes.The review also highlights various challenges in the field that hinder the clinical translation of natural products.
Among the reviewed natural products, actein, salicylate, tanshinone IIA, xanthohumol, honokiol, trichodermin, psorachromene, and protocatechuic acid have been investigated as chemotherapeutic agents with HNSCC cell lines and xenografted animal models, and these products have shown promising targeted molecular mechanisms against HNSCC, making them ideal candidates for further clinical trials for safety and efficacy analyses [24,[41][42][43][44][45]56,65].Furthermore, salicylate and xanthohumol have been investigated to provide synergistic effect with cisplatin and radiotherapy, respectively, making them the strongest candidates for future clinical trials for HNSCC or OPMD patients [42,44].Finally, calcitriol, nimbolide, and neferine were the major natural products investigated in this review; these products showed promising chemoprevention properties against induced-carcinogenesis animal models.We encourage further investigation into the safety and efficacy of these products with human trials, as well as in high-risk OPMD such as erythroplakia and leukoplakia patients [25,47,64].Nevertheless, it is crucial that the results of preclinical studies presented in this manuscript serve only as a principle for further investigations and should not be directly extrapolated into clinical practices without additional detailed evaluation.Preclinical studies, either in vitro or in vivo, provide valuable insights on the potential of natural products as therapeutic agents; however, their efficacy, toxicity profile, and applicability in human patients should be widely explored.Finally, caution must be exercised when interpreting the findings of preclinical studies and their potential implication for clinical trials.

Conclusions
Both chemotherapeutic and chemoprevention approaches showed promising anticancer effects through preclinical studies involving various HNSCC cell lines and animal models via various pathways (Figure 2).However, the lack of extensive molecular mechanisms of natural products and lack of combination of natural products with the current standard of care limits the use of natural products as new chemotherapeutic drugs.The only study that used calcitriol to determine the immunomodulatory effect of natural product in the context of HNSCC highlighted the effort to investigate the role of these natural products since the immune checkpoint inhibitor has been recognized as one of the standards of care for HNSCC patients.The low intrinsic toxicity of natural products in normal cells and significant therapeutic effects toward cancer cells have sparked an interest in oncology studies in recent years.The synergistic effect of natural products with standard of cares, including chemotherapy, radiotherapy, and immunotherapy, has showed promising properties as both alternative and adjunctive chemotherapeutic or chemoprevention agents in cancer treatment or prevention, respectively.As a conclusion, we attempted to provide a comprehensive database of natural products used for in vivo and in vitro preclinical studies involving HNSCC in the recent years, which would facilitate the identification of effective natural products that show promising chemotherapeutic and chemoprevention properties against HNSCC while possessing low toxicity.Natural products have shown to be promising molecular targets for therapy and prevention against HNSCC, making them great alternatives and adjunctive agents in cancer treatment.However, further toxicity profiles should be analyzed for natural products in future clinical trials to ensure the safety and efficacy of natural products against HNSCC.

Figure 1 .
Figure 1.Natural products involved in preclinical trials involving HNSCC cell lines and animal models.

Figure 1 .
Figure 1.Natural products involved in preclinical trials involving HNSCC cell lines and animal models.

Figure 2 .
Figure 2. Various natural products and their respective molecular mechanisms against HNSCC: chemoprevention (natural product name in green), chemotherapeutic (natural product name in black).

Figure 2 .
Figure 2. Various natural products and their respective molecular mechanisms against HNSCC: chemoprevention (natural product name in green), chemotherapeutic (natural product name in black).

Table 1 .
Chemotherapeutic findings from preclinical studies with natural products involving in vitro HNSCC cell lines.

Table 2 .
Chemotherapeutic findings from preclinical studies with natural products involving in vitro HNSCC cell lines and in vivo xenograft models.

Table 3 .
Chemoprevention findings from preclinical studies with natural products on induced carcinogenesis.